… In the current study, erlotinib-resistant human pancreatic adenocarcinoma cells (… erlotinib.
To achieve this, the metabolic characteristics between erlotinib-sensitive (HPAC) and erlotinib-…

… study focused on the investigation and comparison of the inhibitory effects of icotinib and
erlotinib … In this study, the inhibitory effects of icotinib and erlotinib against human UGT1A1 were …

… The applicability of the method was extended to perform a comparative study of the PK of
ERL/LAP following short-term and long-term administration of GTE, compared with their single …

… Erlotinib (ELT) as a small molecule with poor solubility, poor … In the present study, ELT-liposome
and ELT-NLCs were … The obtained data from this study clearly showed that ELT-NLCs …

… of erlotinib versus chemotherapy, then the estimate of the adjusted indirect comparison of
gefitinib versus erlotinib … other TKI-inhibitors could arise from the results of comparative studies. …

… , participants emphasized the usefulness of erlotinib as second-line therapy for lung cancer.
They noted that, although there are no comparative studies, erlotinib could be as effective as …

… compared with erlotinib. We aimed to compare dacomitinib with erlotinib in a phase 3 study.
… The availability of this new generation of EGFR inhibitors prompted comparative studies …

… maintaining efficiency and reducing the number of subjects required for a comparative
study. This approach may offer advantages over conventional phase II cancer trial designs. …

… receiving erlotinib plus fulvestrant and 28 patients receiving erlotinib alone). Overall, the
median PFS was 3.5 months for erlotinib plus fulvestrant and 1.9 months for erlotinib alone [HR …

… The aim of the study was to investigate the impact of erlotinib … Preliminary comparative phase
solubility study indicated … silico computational study, employed to analyze the comparative …